Vaspin (SERPINA12) Genotypes and Risk of Type 2 Diabetes: Results from the MONICA/KORA studies

Kempf, Kerstin; Rose, B.; Illig, Thomas; Rathmann, Wolfgang; Straßburger, Klaus; Thorand, Barbara; Meisinger, Christa; Wichmann, HE; Herder, Christian; Vollmert, Caren

doi:10.1055/s-2008-1081499

Cited by 61 publications

(47 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with these observations, we found that higher serum vaspin concentrations and increased SERPINA12 mRNA expression in human adipose tissue was associated with obesity, insulin resistance and type 2 diabetes [2,3]. In the Kooperative Gesundheitsforschung in der Region Augsburg [Cooperative Health Research in the Augsburg Region] (KORA) study, vaspin genotype was found to be significantly associated with type 2 diabetes independently of obesity [4].…”

Section: Introductionsupporting

confidence: 73%

Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects

Kovacs²,

et al. 2011

View full text Add to dashboard Cite

Aims/hypothesis Vaspin (visceral adipose tissue-derived serpin) was first identified as an adipokine in a rat model of type 2 diabetes, in which it is predominantly secreted from visceral adipose tissue. Serum concentrations of vaspin show a food intake-related diurnal variation. We therefore tested the hypothesis that vaspin plays a role in the regulation of food intake. Methods Vaspin levels in the hypothalamus and human stomach were determined by western blotting. The cerebrospinal fluid concentration of vaspin was measured in five healthy volunteers using an ELISA. Fed 11-week-old female db/db mice were given intraperitoneal injections of 1 mg/kg body weight of vaspin (n=6) or saline (n=6) on experimental days 1, 3 and 4. Changes in food intake and fed plasma glucose concentrations were determined after one intracerebroventricular administration of either 1 μg vaspin or artificial cerebrospinal fluid into 11-week-old female db/db (n=8) and C57BL/6 mice (n=8) up to 6 days after injection. Results We detected vaspin in the hypothalamus of db/db and C57BL/6 mice and in the cerebrospinal fluid of healthy individuals. Both peripheral and central vaspin administration decrease food intake in obese db/db and lean C57BL/6 mice. In db/db mice, vaspin treatment is associated with sustained glucose-lowering effects for at least 6 days after injection. In addition, we demonstrated expression of the gene encoding vaspin in the gastric mucosa in humans, and found that this was subject to regional variations. Conclusions/interpretation Our data suggest a previously unrecognised role of vaspin in the regulation of food intake. We postulate that vaspin inhibits a protease that degrades an anti-orexigenic factor.

show abstract

Section: Introductionsupporting

confidence: 73%

Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects

Kovacs²,

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Vaspin has been considered as a novel link between human obesity and its related metabolic disorders, especially diabetes [5]. Klothin et al [6] reported that the expression of vaspin was high in T2DM.…”

Section: Brief Communication (Original)mentioning

confidence: 99%

Vaspin in newly and previously diagnosed Chinese type 2 diabetic females: a case-control study

et al. 2011

View full text Add to dashboard Cite

Background: Visceral adipose tissue-derived serine protease inhibitor (vaspin) is a novel adipocytokine. Several studies have indicated that vaspin may exert an important role in the development of metabolic disorders. Objective: Evaluate serum vaspin and its relation to clinical parameters in newly and previously diagnosed Chinese type 2 diabetes mellitus (T2DM) females as a case-control study. Materials and methods: One hundred twenty female participants (newly and previously diagnosed T2DM patients) were recruited from an affiliated hospital of Harbin Medical University. Sixty healthy female volunteers from various communities were included as controls. Anthropometric parameters, serum fasting blood glucose, fasting insulin, lipid profile, HbA1c, and vaspin were measured in each participant. Results: Serum vaspin levels were significantly lower in previously diagnosed T2DM patients (0.51±0.29 ng/mL) than in newly diagnosed T2DM patients (0.62±0.28 ng/mL) and healthy controls (0.69±0.31 ng/mL). However, there was no difference in serum vaspin between newly diagnosed T2DM patients and healthy controls. In multiple linear regression analysis, serum vaspin was significantly and positively associated with HbA1c in both newly and previously diagnosed T2DM patients, negatively associated with homeostasis model assessment of insulin resistance in previously diagnosed patients, and positively correlated with age and body mass index in healthy controls. Conclusion: Serum vaspin was significantly lower in previously diagnosed T2DM patients than in newly diagnosed T2DM patients and healthy controls. Serum vaspin might be a predictor of poor glucose control and insulin resistance in T2DM.

show abstract

“…These results were contradictory to the results obtained by Hashemi et al (16), who reported that genotypes carrying the A allele (TA and AA) diminished the risk of MeS in comparison to the wild TT genotype in all tested inheritance models. Kempf et al (8) found that the AA genotype of vaspin rs2236242 confers an increased risk of type 2 diabetes when compared with the TT genotype.…”

Section: Mes (N = 100)mentioning

confidence: 99%

“…This may be due to its antiinflammatory effect (6) or inhibition of proteases that degrade antihyperglycemic and antiorexigenic molecules (7). A single nucleotide polymorphism in intron 4 of a vaspin gene (its approved code by the HUGO Gene Nomenclature Committee is SERPINA12), vaspin rs2236242, was found to be strongly associated with diabetes (8).…”

Section: Introductionmentioning

confidence: 99%

The association of vaspin rs2236242 and leptin rs7799039 polymorphism with metabolic syndrome in Egyptian women

Alnory¹,

Gad²,

Hegazy³

et al. 2016

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: Genetic predisposition is implicated in the etiology of metabolic syndrome. This study aimed to investigate the association of vaspin rs2236242 and leptin rs7799039 polymorphisms with their serum levels and with the risk of developing metabolic syndrome in Egyptian women. Materials and methods:This case control study included 100 Egyptian women with metabolic syndrome and 100 without metabolic syndrome. The genotypes of vaspin rs2236242 and leptin rs7799039 were detected by a methodology based on PCR-RFLP. Serum vaspin and leptin levels were determined by ELISA. Results:The metabolic syndrome group was associated with higher serum vaspin and leptin levels when compared to the nonmetabolic syndrome group. The AA genotype of leptin rs7799039 was associated with metabolic syndrome and with higher serum leptin levels, while the different genotypes of vaspin rs2236242 were not associated with metabolic syndrome or different serum vaspin levels. Conclusion:The AA genotype of leptin rs7799039 was associated with metabolic syndrome and higher serum leptin levels. Serum leptin and vaspin can be used as diagnostic markers of metabolic syndrome.

show abstract

Vaspin (SERPINA12) Genotypes and Risk of Type 2 Diabetes: Results from the MONICA/KORA studies

Cited by 61 publications

References 27 publications

Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects

Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects

Vaspin in newly and previously diagnosed Chinese type 2 diabetic females: a case-control study

The association of vaspin rs2236242 and leptin rs7799039 polymorphism with metabolic syndrome in Egyptian women

Contact Info

Product

Resources

About